Information technology services industry
Rigel Pharmaceuticals Enters into License and Collaboration Agreement with Eli Lilly
Rigel Pharmaceuticals, Inc. and Eli Lilly and Company have announced a strategic partnership to co-develop and commercialize Rigel's R552, a RIPK1 inhibitor, for the treatment of non-central nervous system (non-CNS) diseases. The license and collaboration agreement also aims to develop additional RIPK1 inhibitors for CNS diseases. Under the